current user: public

If you have questions about the server, please let us know.

Query: CPX_91702_91677 Complex of EZRI_HUMAN with M1_I34A1 [Undefined organism], from CSGID

Results of FFAS03 search in PfamA32U
Master-slave alignment(slide right to see more) does not show gaps in the query sequence, use ali links to display alignment between query and templates.
    .   10    .   20    .   30    .   40    .   50    .   60    .   70    .   80    .   90    .  100    .  110    .  120    .  130    .  140    .  150    .  160    .  170    .  180    .  190    .  200    .  210    .  220    .  230    .  240    .  250    .  260    .  270    .  280    .  290    .  300    .  310    .  320    .  330    .  340    .  350    .  360    .  370    .  380    .  390    .  400    .  410    .  420    .  430    .  440    .  450    .  460    .  470    .  480    .  490    .  500    .  510    .  520    .  530    .  540    .  550    .  560    .  570    .  580    .  590    .  600    .  610    .  620    .  630    .  640    .  650    .  660    .  670    .  680    .  690    .  700    .  710    .  720    .  730    .  740    .  750    .  760    .  770    .  780    .  790    .  800    .  810    .  820    .  830    .
# Score Template Links and tools%idFirst MPKPINVRVTTMDAELEFAIQPNTTGKQLFDQVVKTIGLREVWYFGLHYVDNKGFPTWLKLDKKVSAQEVRKENPLQFKFRAKFYPEDVAEELIQDITQKLFFLQVKEGILSDEIYCPPETAVLLGSYAVQAKFGDYNKEVHKSGYLSSERLIPQRVMDQHKLTRDQWEDRIQVWHAEHRGMLKDNAMLEYLKIAQDLEMYGINYFEIKNKKGTDLWLGVDALGLNIYEKDDKLTPKIGFPWSEIRNISFNDKKFVIKPIDKKAPDFVFYAPRLRINKRILQLCMGNHELYMRRRKPDTIEVQQMKAQAREEKHQKQLERQQLETEKKRRETVEREKEQMMREKEELMLRLQDYEEKTKKAERELSEQIQRALQLEEERKRAQEEAERLEADRMAALRAKEELERQAVDQIKSQEQLAAELAEYTAKIALLEEARRRKEDEVEEWQHRAKEAQDDLVKTKEELHLVMTAPPPPPPPVYEPVSYHVQESLQDEGAEPTGYSAELSSEGIRDDRNEEKRITEAEKNERVQRQLLTLSSELSQARDENKRTHNDIIHNENMRQGRDKYKTLRQIRQGNTKQRIDEFEALXMSLLTEVETYVLSIIPSGPLKAEIAQRLEDVFAGKNTDLEVLMEWLKTRPILSPLTKGILGFVFTLTVPSERGLQRRRFVQNALNGNGDPNNMDKAVKLYRKLKREITFHGAKEISLSYSAGALASCMGLIYNRMGAVTTEVAFGLVCATCEQIADSQHRSHRQMVTTTNPLIRHENRMVLASTTAKAMEQMAGSSEQAAEAMEVASQARQMVQAMRTIGTHPSSSAGLKNDLLENLQAYQKRMGVQMQRFKLast
1 -50.100PF08289.11; M1_I34A1/158-252; Influenza Matrix protein (M1) C-terminal domain  ali follow..  100  1........................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................QHRSHRQMVTTTNPLIRHENRMVLASTTAKAMEQMAGSSEQAAEAMEVASQARQMVQAMRTIGTHPSSSAGLKNDLLENLQAYQKRMGVQMQRFK 95
2 -25.500PF09380.10; FARP2_MOUSE/238-328; FERM C-terminal PH-like domain  ali follow..  23  1.................................................................................................................................................................................................................DREGTKINLAVSHMGVLVFQGTTKIN---TFNWSKVRKLSFKRKRFLIKLHPEYQDTLEFLLGSRDECKNFWKICVEYHTFFRLSDQPKP............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................ 91
3 -16.900PF09379.10; E41L4_DANRE/15-83; FERM N-terminal domain  ali follow..  27  1........VLLLDESQQQGIKKSTRGSVVLDYVFSHVNLAETEYFGVRYCDRSHQTFWLDPSKTLAEHK.................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................. 67
4 -9.430PF07964.11; G8JR69_ERECY/11-759; Rec10 / Red1  ali follow..  21..................................................................................STYSKGIGQLLINDFQMCNYLVELLSNVFTRK---TNKTGVVMPPNL-------WDDEEKNALLFNNPDY-P------------------------YRGKHGDASVVNFI-----WKRFGPFFTNLVKATCVKYTLANGRSKPLSKSPWCSIQ-NKIYIWTGVEVIKDLKEQIRIKLLKPFLEVFRLEFDSTANSE----------TFMNATKIPKISEVQNFIAL----KFPSSFEDEILDSSMPLPDDHQPLSDNLGLNLGDEPVVSHNIGEEDIPRQQLSTTQRSGKNPLATPDQTVDKGIAQDLEDEWDLRQSSLATAKLDIHSLKTPTSKEVEIVEDEQSPLVMAQKRRLARATSRTLEALKQEFGVENINSSSQSSDEGTSQHELSESSLSSLEIEKFESRKRTAAQKAAKRVTAALQNTKAASRSSNTNKDNERSAANSNAKAKNKATSAVKGDMGLAALDDIFAIPSIKPKKQQKLNNYKEVVYVPSRDPTNDKGITKKSRVKKKQTALPVKRKHDDGDDATGKDSKAVQRQSFRELTADTDMTVQNKQVSVTPAQEQKDLQTPKTPEKVNKTRYKRKRVIAKGTAFNLELPSPPPLPLTEKSDTTTSNNLQQPSRNTSMTSIEPLAPGNLTIKNELTESTTLANTSATSLAFTNKLQEQIFSSISSFSNDLVKKISIINEDNKIVRQFSEKYQKLFHDLQFQHDVNNMSCFVSEF-----------KDLL-HLPEEELIKIIRNKKF. 749
5 -9.350PF02691.15; VACA3_HELPX/43-1023; Vacuolating cyotoxin  ali follow..  14  794................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................NKTANNTTIAVNLGNNSTPTNSTTDTTNLPTNTTNNARFASYALIKNAPFAHSATPNLVAIQHDFGTIESVFELANRSSDIDTLYANSGAQSHDAGYARTMIDATSANEITQQLNAATTLNNIA-SLEHKTSGLQTLSLSNAMILNSRLVNL---SRKHTNHSFAKRLQA-LKD-----QRF. 980
6 -8.420PF04388.12; F7E2N6_XENTR/7-705; Hamartin protein  ali follow..  1................................VWDHLYLLESS---LQQLD--------QIHTLIRDHLSADRSPILVNNLVDHYVETGSEQAMLILSMV-LLDKINEYLVKAA-----PTLTLLGHVILKCLKVDNDVVVLTTGVLVLITVLPMQSGKQHLYEFFDIFGRLATWCLKNPGRVAKICLVHLHASVYAL-LYGM--YPCN--------------------------------------VSFLRSHYSMK---ENLETF------EEIVKPMMEHVRIHPELVTGSKDHEL----------DPSRWRRLETHDIVVE----------------AKISLDPSEASYEEGYSPLSNRLRQRQHDTTSSPYTEIGCNYGSNASTPFSTPRMCAHSASIHSGGIELLQDSIWSPSTICGMTTPPNSPANVLADAAHSSSRPHSKVLYTPVGGKITPLGTPATSPPPPSNSEECTPAAGASLTLTPHKKNESFDPGRSLVNRQLLSKGEKSADESPKTQKTVYLSELPDIIGDLAADHNSTEEEQETRAAICQELSQITTADPEPTVLRGGFDSP---------------FSLRCDSQPSSQKKFPSYGVGHIPEHSAPNKLHYSAPHDSSKQAFTPIEPPNGTENAADSGKPPSNNSLPSAVDIFTPQVQRNVSCFSLPPYDHLFELALPKTANMFVCRKNEE-----------------------------LCRRGKGSLEEGEEGAFSVSPAEVLDRLIQLGADAHTKELSKLSLPSKAADWTHFGGSPPTDEIHVLRN----------LHNQLL--YERFKRQQHAQRNR.. 697
7 -7.100PF05703.11; M4FF47_BRARP/18-307; Auxin canalisation  ali follow..  18  175.................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................AAVSVAGVAAAVAAIAAATAASSSAGKDEQMAKTDMAVASAATLV--AAQCVEAAEVMGAEREHLAYVVSSAVNVRDIMTLTAGAATALRGVATLKARAMKEVWNMDK--G....... 290
8 -6.680PF15427.6; H0XCQ7_OTOGA/21-407; S100P-binding protein  ali follow..  18  286......................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................PVLQTKARTNVPTFSQSNLEQQKQIYLRSVIAHIEDPEDSNQDVAGELVHHMQNPKW-Q-------HPS-------DLMRNLTQWVDRNMRSHHRFQ 385
9 -6.590PF07837.12; R6RB74_9CLOT/5-181; Formiminotransferase domain, N-terminal subdomain  ali follow..  16  9........................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................SEGRDLEKIEKIVECFRAKKGVRLLDYQTRLVVTVIGEPEPLRDAVASFGRAVELIDMTKHEGQHPRMGA-CRNATLEEADALAKEVAKTV.... 112
10 -6.580PF00769.19; EZRI_BOVIN/338-581; Ezrin/radixin/moesin family  ali follow..  86  1.................................................................................................................................................................................................................................................................................................................................................EQMMREKEELMLRLQDYEEKTRKAEKELSDQIQRALKLEEERKRAQEEAGRLEADRLAALRAKEELERQAADQIKSQEQLATELAEYTAKIALLEEARRRKENEVEEWQLRAKEAQDDLVKTREELHLVMTAPPPPPVY-----EPVNYHVHEGPQEEGTELSAELSSEGILDDRNEEKRITEAEKNERVQRQLMTLTSELSQARDENKRTHNDIIHNENMRQGRDKYKTLRQIRQGNTKQRIDEFEAM............................................................................................................................................................................................................................................................. 244

FFAS is supported by the NIH grant R01-GM087218-01
1 3 7 8 0 7   jobs submitted since Jan 1, 2011
Comments and questions to: webmaster

Selected papers from Godzik Lab
Ying Zhang, Ines Thiele, Dana Weekes, Zhanwen Li, Lukasz Jaroszewski, Krzysztof Ginalski, Ashley Deacon, John Wooley, Scott Lesley, Ian Wilson, Bernhard Palsson, Andrei Osterman, Adam Godzik. Three-Dimensional Structural View of the Central Metabolic Network of Thermotoga maritima. Science. 2009 Sep 18;325(5947):1544-9.

Mayya Sedova, Mallika Iyer, Zhanwen Li, Lukasz Jaroszewski, Kai W Post, Thomas Hrabe, Eduard Porta-Pardo, Adam Godzik Cancer3D 2.0:: interactive analysis of 3D patterns of cancer mutations in cancer subsets. Nucleic Acids Research, gky1098 2018; Published on November 8 2018.

Sasin JM, Godzik A, Bujnicki JM. SURF'S UP! - protein classification by surface comparisons. J Biosci. 2007 Jan;32(1):97-100.